Cheson and Leonard: ASH highlights - New Combinations

[Guest guest]

Non Hodgkin Lymphoma: New Drug Combinations

Bruce D. Cheson, MD; P. Leonard, MD

Here the distinguished chair and co-chair of CALGB discuss ASH findings and

future directions.

http://bit.ly/fsCCI9

Link to discussed protocol:

R-CHOP Versus. Dose-Adjusted EPOCH-R With Molecular Profiling

Condition: Previously untreated Diffuse Large B-cell Lymphoma:

http://bit.ly/8NNNBG

More info on single agents discussed (and other) with links to trials

http://www.lymphomation.org/treatment-pipeline.htm

.... Targeted agents showing activity in clinical trials:

ABT-263 | carfilzomib |btk-inhibitor | CAL101 | Everolimus | GA-101 |

Inotuzumab Ozogamicin Lenalidomide | obatoclax mesylate | SGN-35 |

Temsirolimus | cd22-fractionated-RIT

Karl Schwartz

President, Patients Against Lymphoma

www.Lymphomation.org

Evidence-based information on lymphoma, independent of health industry

funding